Takeda: Primary Endpoint Not Achieved In Orteronel Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Japan’s Takeda announced on July 26 that the primary endpoint in Phase III trials with their non-steroid androgen inhibitor orteronel was not achieved.
You may also be interested in...
QUOTED. 5 August 2020. Eric Fanning.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Need a specific report? 1000+ reports available
Buy Reports